Pharvaris N.V.
NASDAQ:PHVSBiotechnology
-$0.64 today
- Market cap
- $2.22B
- Beta
- -2.33
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.59
Volume 0.28M
Average 0.31M
Returns on capital
Pharvaris N.V. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-64.8%
avg -42.1%
ROIC
-62.4%
avg -43.4%
ROA
-58.3%
avg -38.6%
Analysis
ROA is currently the strongest return metric at -58.3% versus its period average of -38.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Berndt Axel Edvard Modig | Co-Founder, Chief Executive Officer & Executive Director | EUR 1.54M | 67 | — | — |
Anne Lesage | Chief Early Development Officer | — | 65 | 73.97K | 0.11% |
Maggie Beller | VP & Head of Corporate and Investor Communications | — | — | — | — |
Maryann Cimino | Director of Corporate Relations | — | — | — | — |
Wim Souverijns | Chief Commercial Officer | — | 55 | 39.02K | 0.06% |
Anna Nijdam | Head of Strategic Finance & Principal Accounting Officer | — | 45 | 46.27K | 0.07% |
Peng Lu | President | — | 48 | 109.81K | 0.16% |
Annick Deschoolmeester | Chief Human Resources Officer | — | 53 | 45.00K | 0.06% |
David W. Nassif | Chief Financial Officer, Chief Legal Officer & Corporate Secretary | — | 72 | 113.80K | 0.16% |
Stefan Abele | Chief Technology Operations Officer | — | 56 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 12, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
70
$32.91M
Net Transaction Value
−$32.91M
Net selling
Most Active
Lesage Anne
18 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 23, 26Sep 23, 2026 | Monges Viviane Direct | Sell | $395.5K$395,523.98 |
| Sep 22, 26Sep 22, 2026 | Schikan Johannes Gerardus Christiaan Petrus Direct | Sell | $29K$28,952.00 |
| Sep 21, 26Sep 21, 2026 | Nassif David W. Direct | Sell | $218.8K$218,800.80 |
| Sep 17, 26Sep 17, 2026 | Bjork Elisabeth Direct | Sell | $2M$1,989,408.75 |
| Sep 17, 26Sep 17, 2026 | Glassman Robert Direct | Sell | $558.8K$558,812.40 |
| Sep 17, 26Sep 17, 2026 | Lesage Anne Indirect | Sell | $765.5K$765,466.00 |
| Sep 17, 26Sep 17, 2026 | Schikan Johannes Gerardus Christiaan Petrus Direct | Sell | $7M$7,000,000.00 |
| Sep 17, 26Sep 17, 2026 | Lu Peng Direct | Sell | $3.5M$3,500,000.00 |
| Sep 15, 26Sep 15, 2026 | Abele Stefan Andreas Direct | Sell | $1.7M$1,716,187.50 |
| Sep 15, 26Sep 15, 2026 | Abele Stefan Andreas Direct | Sell | $54.9K$54,937.54 |
1–10 of 70
Summary
Insiders reported 0 buys worth $0.00 and 70 sells worth $32.91M over the last 12 months. That adds up to net selling of $32.91M. Lesage Anne was the most active insider with 18 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A0 analysts |
| Net Income | N/A | N/A | N/A | N/A0 analysts |
| EBIT | N/A | N/A | N/A | N/A0 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Pharvaris N.V. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about PHVS's management, answered from reported figures.
Who manages PHVS?
Pharvaris N.V. (PHVS) lists 10 active executives. The top listed executive is Anne Lesage, Chief Early Development Officer.
Are PHVS insiders buying or selling?
Recent insider activity shows net selling of $43.30M.
Continue the stock analysis
Jump to another research area for this company.